Study S000614

A Phase 1, Randomized, Single-blind, Placebo-controlled, Multiple-dose, Two-sequence, Cross-over Study to Evaluate the Effect of Ranolazine on Glucagon Secretion in Subjects With Type 2 Diabetes Mellitus, Followed by An Open-label, Single Dose, Exenatide Active-control Period

ClinicalTrials.gov record

Registration

Registration: NCT01843127
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE1
Masking: SINGLE
Status: COMPLETED
Enrollment: 24
Start: 2013-04
Primary completion: 2013-09
Lead sponsor: Gilead Sciences
Conditions: Type 2 Diabetes Mellitus
Interventions: DRUG:Ranolazine; DRUG:Placebo; DRUG:Exenatide
Results posted: FALSE

Registered primary outcomes

Area under the concentration-time curve (AUC) of plasma glucagon during the standard meal test (SMT) [Days 5, 10, and 14]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.